We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bayer Ord | LSE:BYR | London | Ordinary Share | DE000BAY0017 | REG SHS |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.93 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 55.93 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/3/2024 | 12:17 | ALNC |  UPDATE: Bayer denies split-up as "not now" while swings to annual loss |
| 05/3/2024 | 10:13 | ALNC | TOP NEWS: Bayer swings to annual loss on falling sales as costs rise |
| 04/3/2024 | 09:35 | ALNC | Bayer acquires European marketing rights to acoramidis heart treatment |
| 19/2/2024 | 18:17 | ALNC | TOP NEWS: Bayer slashes dividend in commitment to cutting down debt |
| 13/2/2024 | 17:07 | ALNC | IN BRIEF: Bayer notes first patient in GenePHIT trial |
| 18/1/2024 | 06:09 | ALNC | Chemical firm Bayer confirms 'significant' workforce cuts in Germany |
| 11/1/2024 | 14:29 | ALNC | CORRECT: RTW Biotech's manager invests USD127 million in Ji Xing |
| 08/1/2024 | 18:12 | ALNC | Bayer reports progress on two fronts for menopausal drug, elinzanetant |
| 08/1/2024 | 12:27 | ALNC | RTW Biotech Opportunities invests USD127 million in investee Ji Xing |
| 19/12/2023 | 05:52 | ALNC | Bayer's Monsanto to pay USD857 million over chemicals in school |
Bayer Ord (BYR) Share Charts1 Year Bayer Ord Chart |
|
1 Month Bayer Ord Chart |
Intraday Bayer Ord Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/10/2008 | 10:12 | A Buyer for BAYER | 25 |
| 28/10/2001 | 20:23 | ANTHRAX - Bayer AG manufacture Cipro | 15 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 01/7/2008 05:57 by waldron Bayer "buy," target price raised06/30/08 - Deutsche Bank LONDON, June 30 (newratings.com) - Analyst Tim Jones of Deutsche Bank maintains his "buy" rating on Bayer AG (BAY). The target price has been raised from 67 to 69. In a research note published this morning, the analyst mentions that a majority of the company's businesses present robust growth prospects. The industry outlook for the CropScience business is extremely healthy in the foreseeable future, aided by demand growth and price increases, the analyst adds. Potentially significant newsflow is expected regarding the development of the pharmaceutical pipeline in Bayer's Healthcare in the next six-to-eighteen months, Deutsche Bank says. |
Posted at 09/12/2007 09:07 by ariane J&J, Bayer Pill Caused Fewer Clots Than Sanofi Drug in Study By Lisa Rapaport and Luke Timmerman Dec. 8 (Bloomberg) -- Bayer AG and Johnson & Johnson's experimental blood thinner led to fewer clots and deaths in patients after hip surgery than a widely used therapy sold by Sanofi-Aventis SA, a study found. About 1.1 percent of patients had serious blood clots or died on the Bayer and J&J pill, rivaroxaban, compared with 3.7 percent of those taking Sanofi's injected medicine, Lovenox, according to research reported today at the American Society of Hematology meeting in Atlanta. Both drugs had similar rates of bleeding, a side effect of anti-clotting medications. Rivaroxaban may help J&J and Bayer take market share from the injectable Lovenox, Sanofi's best-seller with $3.5 billion in sales last year. Bayer, Germany's largest drugmaker, asked European regulators to allow sale of the drug under the brand name Xarelto in October, and has projected peak sales of $2.9 billion. J&J, of New Brunswick, New Jersey, has said it will seek U.S. marketing approval in the second half of 2008. ``The results were quite astonishing,'' said Bengt Eriksson, an orthopedic surgeon at Sahlgrenska University Hospital in Gothenburg, Sweden, and the study's lead author, in an interview. ``It was a big surprise,'' for the new drug to demonstrate superior effectiveness, instead of merely showing about equal effectiveness, he said. Patients were given either Lovenox or rivaroxaban for five weeks after hip-replacements. Studies of the J&J and Bayer drug in other major orthopedic surgery will be presented Monday. Dangerous Clots Blood clots are usually part of the body's healing mechanism. If they form in one of the veins deep in the body, like those in the legs, the jelly-like mass can block blood flow causing the leg to swell. If a clot breaks lose, it can travel to the lungs or brain, a life-threatening situation. Around 300,000 Americans die every year from these clots, more than the number who die from AIDS, breast cancer and car accidents combined, according to the American Society of Hematology. ``This drug was measured against Lovenox, which is the gold standard, and we got more efficacy without paying a price in terms of any extra bleeding,'' said Lloyd Haskell, a vice president at J&J's pharmaceutical research and development unit, in a telephone interview. If approved by regulators, rivaroxaban will be marketed by J&J in the U.S. and by Bayer in the rest of the world. To contact the reporter on this story: Lisa Rapaport in New York at Lrapaport1@bloomberg Last Updated: December 8, 2007 11:14 EST |
Posted at 07/11/2007 17:49 by waldron Bayer "buy," target price raised - updateWednesday, November 07, 2007 9:04:44 AM ET Dresdner Kleinwort Wasser. LONDON, November 7 (newratings.com) - Analysts at Dresdner Kleinwort maintain their "buy" rating on Bayer AG (BAY.ETR), while raising his estimates for the company. The 12-month target price has been raised from 67 to 70. In a research note published this morning, the analysts mention that the company's CropScience division posted robust sales and margins for 3Q. Bayer's key products in the Healthcare division, Nexavar, Betaferon and Yasmin, posted robust results for the three-month period, with disappointing sales of women's health product, Trasylol, and diagnostic imaging, the analysts say. The diluted EPS estimates for 2007, 2008 and 2009 have been raised from 4.61 to 4.76, from 4.23 to 4.32 and from 4.80 to 5.03, respectively. |
Posted at 06/11/2007 11:00 by waldron Bayer Ag Bayer Q3 pre-ex EBITDA beats consensus as Schering outperforms UPDATE(Recasts intro, adds details on projected dividend, number of jobs cut) LEVERKUSEN, Germany (Thomson Financial) - Bayer AG said EBITDA before one-time charges rose 6.9 pct to 1.559 bln eur, up from a restated 1.459 bln last year, helped by higher sales of the Yasmin and Mirena contraceptives, acquired as part of the takeover of rival Schering. This surpassed the 1.546 bln eur average estimate compiled in a Thomson Financial News survey of seven analysts. Third-quarter revenue advanced 4.5 pct to 7.793 bln eur, compared with an average analyst forecast of 7.764 bln. "Not least because of the Schering acquisition, we have enhanced our earnings power (in the long term)," chief executive Werner Wenning said. "The results were solid," said Martin Brunninger, an analyst at Cazenove in London. "But once again the main profit contributors and growth drivers were Schering products and pharmaceuticals from the traditional Bayer business were very disappointing." Bayer last year bought rival German drug maker Schering for 17 bln eur. Yasmin generated 35 pct more revenue than last year, while the rate was 29.7 pct for Mirena, the two fastest growing drugs among the company's 10 best selling pharmaceuticals. Brunning also pointed to Trasylol, an injection to prevent excessive blood loss during surgery which Bayer yesterday temporarily pulled off global markets because of reported side-effects. Trasylol is part of Bayer's traditional business, as is the Cipro antibiotic, which saw a loss in sales of 17.9 pct in the third quarter. Bayer recalculated last year's figure to exclude sold businesses such as H.C. Starck and Wolff Walsrode. The German company also said it expects the 2007 margin of EBITDA before one-time charges over sales to reach at least 20.3 pct, up from 19.3 pct last year. Chief executive Wenning has declared EBITDA before one-time charges as a percentage of sales Bayer's yardstick of success, having said previously the margin is set to exceed 20 pct this year and rise above 22 pct by 2009. The full-year sales target was also increased, to more than 32 bln eur, a gain of about 6 pct when excluding the effect of portfolio changes and currency swings and higher than the earlier comparable goal of an about 5 pct rise. Quarterly revenue at the HealthCare unit, Bayer's largest, rose 5.7 pct to 3.680 bln. The company sees the 2007 pre-exceptional EBITDA margin at the division, whose products range from the Aspirin painkiller to blood-clotting drug Kogenate and the Betaferon multiple sclerosis injection, at more than 25 pct. The previous goal was to reach 25 pct. Wenning said he deems the experimental anti-thrombosis pill Xarelto Bayer's most promising product, saying it has "blockbuster potential". In addition to the four uses Xarelto is being tested for, a further indication for hospitalised patients with internal diseases will be pursued. Other drugs that will drive the unit's expansion include the Nexavar kidney cancer treatment, which was recently cleared to treat liver cancer patients in Europe as well. Bayer's CropScience unit posted a 10.3 pct revenue gain on strong demand for pesticides in Latin America. Pre-exceptional EBITDA jumped 16.8 pct to 167 mln eur at the unit, "due largely to higher volumes", the company said. The company-wide net profit soared to 1.175 bln eur, up from 320 mln eur last year on tax effects. Bayer had earlier said it would free up 900 mln eur in the third quarter money set aside for future tax liabilities because of a cut in the corporate tax rate next year. Bayer also said it plans to restructure its MaterialScience unit and to cut jobs there to save 300 mln eur a year by the end of 2009. This will prompt total special charges of 150 mln eur to 200 mln in 2008 and 2009, it added. Job cuts, 400 to 500 in total, will be pursued in a "socially compatible way and through normal attrition", and should be achieved without redundancies, Wenning said. The dividend paid out for 2007 will be "based" on 30 pct to 40 pct of full-year core earnings per share, a profit measure that excludes discontinued operations and write-downs and integration costs related to the Schering takeover, Bayer said. ludwig.burger@thomso lb/slj/lb/wj |
Posted at 26/10/2007 14:24 by grupo guitarlumber Bayer "overweight," target price raisedFriday, October 26, 2007 8:49:24 AM ET J.P. Morgan Securities LONDON, October 26 (newratings.com) - Analysts at JP Morgan reiterate their "overweight" rating on Bayer AG (BAY.ETR), while raising their estimates for the company. The 12-month target price has been raised from 70 to 73. In a research note published this morning, the analysts mention that there is a 60% probability of the company's Rivaroxaban product achieving peak sales of 5 billion. Bayer's share price is expected to be supported by the improved outlook for the Consumer Health division, oral contraceptives and Kogenate margins, the analysts say. The EPS estimates for 2007 and 2008 have been raised from 3.81 to 3.82 and from 4.19 to 4.21, respectively. |
Posted at 17/9/2007 10:48 by ariane Bayer Ag Novartis CEO rules out major pharma merger; no comment on Bayer buy speculationZURICH (Thomson Financial) - Novartis AG chief executive Daniel Vasella has ruled out a merger of major players in the pharmaceutical market, while again declining to comment on rumours linking the company with a takeover of German rival Bayer AG. In an interview with French economic newspaper La Tribune, he said he has "no indication that could confirm the rumours of a merger between major players" in the sector. In the case of Novartis, he pointed out that investments in R&D has grown some 90 pct since 2002. That is faster than revenue growth, and is "not sustainable", he said. However, a merger is "not the answer", he added. "It would be an error to just base any acquisitions on the price," he said, adding that the company has to make sure that it meets its quality criteria and it can build on it. Asked about recent market speculation linking the Swiss pharma group with a bid for German rival Bayer, Vasella once again declined to comment. The Basel-based drug maker has been hit by the suspension of constipation drug Zelnorm as well as by generic competition for some of its key drugs. But last Wednesday, Novartis has projected that it should return to "strong" growth territory by the second half of 2008, including double-digit growth for the phamarceuticals division. Huimin.neo@thomson.c at/hmn/ra |
Posted at 15/9/2007 06:16 by ariane Bayer initiated with "outperform"Friday, September 14, 2007 10:21:29 AM ET Bear Stearns LONDON, September 14 (newratings.com) - Analyst Richard Vosser of Bear Stearns reinitiates coverage of Bayer AG (BAY.ETR) with an "outperform" rating. The target price is set to 75. In a research note published this morning, the analyst mentions that the company's Healthcare business is expected to generate 18.9% EPS growth in 2007-2011 and is unlikely to reach an earnings trough up to 2015. Despite the high quality of the Healthcare business, Bayer's share price reflects the value of this business in-line with that of the European large-cap pharma peers, the analyst says. While Xarelto has the potential to become a multi-billion euro product over the next ten years, Nexavar may become a blockbuster in liver cancer, Bear Stearns adds. |
Posted at 09/9/2007 10:25 by ariane Bayer "buy"Tuesday, September 04, 2007 7:19:03 AM ET Dresdner Kleinwort Wasser. LONDON, September 4 (newratings.com) - Analyst Tero Weckroth of Dresdner Kleinwort maintains his "buy" rating on Bayer (BAY.ETR). The target price is set to 67. In a research note published this morning, the analyst mentions that the company's recent management roadshow was encouraging. Despite the 43% appreciation in Bayer's share price year-to-date, the current valuation of the company's stock is attractive, the analyst adds. |
Posted at 09/9/2007 10:22 by ariane Bayer's Drug PipelineMay Have a Big Winner By GEORGE FREY September 9, 2007 The only time many American investors think of Bayer (BAY) is when they have a headache. But the German company could be worth considering by those who want to diversify their U.S. stock holdings. The pharmaceutical and chemical maker, whose American depositary shares trade on the New York Stock Exchange, just reported strong quarterly results. It has a promising product pipeline and good profit outlook. And it's even the subject of takeover rumors. While most analysts doubt there's substance to the takeover speculation, it's clear what Bayer's attractions would be: A restructuring and a slew of purchases and divestitures have left the concern more efficient and more focused on the bottom line. Bayer's second-quarter profit rose 46%, to 660 million euros ($904 million) from 452 million euros a year earlier. Sales jumped 22%, to 8.22 billion euros. The results were bolstered by inclusion of drug maker Schering, which Bayer bought in 2006. (Schering isn't related to the U.S.'s Schering-Plough.) Bayer Chief Executive Werner Wenning won't comment on the takeover rumors, which have Switzerland's Novartis as a possible suitor. (Novartis hasn't publicly commented, either). But he voices a bright outlook for Bayer's core health-care division. Bayer predicts that 2007 sales will rise more than 10% above 2006's 28.96 billion euros. And with some 20 drugs in Phase III testing, 17 in Phase II and 14 in Phase I, Bayer's future looks better than many rivals', says Andrew Benson, a Citigroup analyst in London. He calls the anti- coagulant drug Rivaroxaban, aimed at helping stroke victims, "the jewel in the crown." Munich-based UniCredit analyst Isabella Zinck says Rivaroxaban could go on the market at the end of 2008 in Europe, and in 2009 in the U.S. Johnson & Johnson, which is sharing in Rivaroxaban's development costs, will get rights for primary-care sales in the U.S. Bayer will get the rights to U.S. specialty-care sales and sales outside the U.S. Mr. Benson has a buy rating on Bayer with a target price of about $88 for its American depositary receipts, which traded recently at about $76. |
Posted at 25/10/2001 18:12 by brendanmoyles Listed on the Frankfurt and other European exchanges much more apealing price if you want to deal in EuroBAYER AG (575200) 34.75 EUR Frankfurt 19:30 CET Quotes 17Oct2001 % Change -0.14% Open 35.60 EUR Low 33.90 Net Volume 259,325 % Change based on prev. close Fundamentals 52 Wk High 57.80 52 Wk Low 24.05 Dividend 0.34 Div Date 30/4/2001 Market Cap 25,379 M Div Yield - P/E Ratio 13.96 EPS 2.49 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
